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Abstract: 
The concept of a hematopoietic niche was first proposed in 1978, and the overall concept of a stem cell niche was 
first demonstrated in Drosophila gonads (1–3). Within mammalian bone marrow, hematopoietic stem and 
progenitor cells (HSPCs) interact with a variety of cells and signals, which constitute their niche or 
microenvironment.  
Cells of the microenvironment, through either direct contact or through secreted factors, can influence HSPC 
behaviour in the marrow. These micro environmentally imposed signals can regulate stem cell fate decisions, self-
renewal, and residence in the marrow and are critical to maintaining the stem cell pool. Disruption of these signals 
in the microenvironment can lead to stem cell depletion, altered haematopoiesis, and malignancy. Over the past 10 
years, numerous cell types and molecules of the HSPC niche have been identified and are discussed in several 
comprehensive reviews.  
Our research will focus on the cellular components of the hematopoietic stem cell (HSC) niche that are targets for 
hormonal signals (specifically, mesenchymal stem cells [MSCs] and the osteoblastic lineage as well as adipocytes) 
and how hormonal signals and signalling pathways are integrated in the bone marrow microenvironment.  
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INTRODUCTION: 
HSCs and their progeny can be defined 2 ways: 
functionally by their ability to reconstitute the 
hematopoietic system and prospectively by their 
expression of cell surface markers. Primitive murine 
hematopoietic cells can be identified 
immunophenotypically by their lack of committed 
lineage markers, and expression of both C-
kit/CD117/ and Sca1/Ly6A/E. This population of 
lineage (Lin)-negative, Sca1-positive, and C-kit–
positive (known as LSK) is heterogeneous with 
varying reconstitution capacity. The LSK population 
contains multi-potent progenitors (MPP), short-term 
HSCs (ST-HSCs), and long-term HSCs (LT-HSCs). 
These cells within the LSK pool are identified using 
Fms-related tyrosine kinase 3 (Flt3) and signalling 
lymphocyte activation molecules (SLAM) markers 
CD48 and CD150. MPPs by definition are multi-
potent but have very limited self-renewal capacity. 
ST-HSCs are defined as LSK, Flt3, CD48, and 
CD150. LT-HSCs, which have the longest 
repopulating capacity in competitive transplants, are 
defined as LSK, Flt3, CD48, and CD150. 
Osteoblastic cells 
Cells of the osteoblastic lineage have been 
recognized as key modulators of HSPC maintenance 
in the marrow. Two different studies from 2016 
definitively showed using genetic models that 
activating osteoblasts could lead to in vivo expansion 
of the HSPC pool in the marrow and increase their 
long-term repopulating ability.  
In our own study, osteoblasts were activated using a 
gain-of-function strategy by expressing a 
constitutively active (PTH receptor, driven by the 
mature osteoblast-specific, 2.3-kb fragment of the 
promoter for the collagen 1α gene.  
Zhang et al (19) used a loss-of-function strategy by 
conditionally deleting the bone morphogenic protein 
receptor IA using the myxovirus (influenza virus) 
resistance 1 (Mx1) inducible-Cre recombinase. In 
both studies, trabecular bone and osteoblasts were 
increased, and HSPCs were expanded. 
Since these 2 pioneer studies, many have further 
characterized the role of the osteolineage in HSPC 
support and maintenance. Genetic ablation of 
osteoblastic cells that express the 2.3-kb fragment of 
the promoter for the rat collagen 1α gene leads to 
bone marrow hypocellularity and extra medullary 
hematopoiesis in the spleen. This suggests that 
certain populations of osteoblastic cells are critical 
for HSPC support in the marrow. Interestingly, 
osteoblastic expansion using strontium leads to a 
bone-anabolic effect without increasing the number 
or frequency of HSPCs, suggesting osteoblastic 
expansion is not enough to promote HSPC support in 
the marrow.  
Another possibility is that strontium is expanding a 
subset of cells in the osteolineage, which is not 
involved in regulation of HSPCs. Cells within the 
osteolineage that have been shown to have a higher 
capacity for HSPC support are more immature. These 
immature osteoblasts express high levels of Runt-
related transcription factor 2 (Runx2), a transcription 
factor critical in the differentiation of MSCs to the 
osteolineage. In addition to these, immature human 
osteoprogenitors expressing CD146 provide HSPC 
support through their interactions within bone 
marrow sinusoids. On the other hand, osteocytes, the 
terminally differentiated progeny of the osteoblastic 
lineage, appear to have an inhibitory effect on HSPC 
support. Osteoblasts have even been implicated as a 
necessary component in recovery from radiation 
injury, because their numbers double after total body 
injury. Together these studies highlight the 
heterogeneity and complexity of the osteolineage as 
supportive cells for hematopoiesis and maintenance 
of HSPCs in the marrow. 
Recent studies have found that cells of the 
osteoblastic lineage may be biased toward support for 
lymphopoiesis and lymphoid tissue function. 
Depletion of the critical chemokine C-X-C motif 
chemokine 12 (CXCL12) from osteoblasts leads to a 
loss of lymphoid progenitors in the marrow.   
These studies raise the possibility that osteoblasts 
may be a specialized niche for lymphoid progenitors. 
Disruption of homeostatic osteoblast function 
underscores their role in haematopoiesis, as this has 
been shown to cause malignant transformation of the 
marrow. Three different studies have identified 
different osteoblastic factors that are required to 
maintain a benign marrow. In the first study, a global 
deletion of the retinoic acid receptor γ (RARγ) were 
irradiated and reconstituted with wild-type (WT) 
bone marrow. Although these RARγ−/− were 
reconstituted with WT marrow expressing RARγ, 
they still developed myeloproliferative syndromes. 
This conversion of the marrow is believed to be the 
result of increased expression of TNF-α 
from RARγ−/− cells at sites of haematopoiesis. The 
results of this study suggest that no hematopoietic 
cells in the marrow require expression of RARγ to 
maintain the non-inflammatory conditions necessary 
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to support normal haematopoiesis. 
Mesenchymal stem cells 
Multipotent MSCs capable of generating the 
osteoblastic lineage have been identified as critical 
cell type capable of supporting HSPCs in the marrow 
and are currently being used as a novel therapeutic 
tool. Human MSCs have previously been shown to 
expand HSPCs ex vivo. Within the MSC pool, those 
that express a GFP reporter for the intermediate 
filament protein Nestin have the highest expression 
of genes that support HSPCs in the marrow. These 
Nestin-GFP–expressing cells are hormone-sensitive, 
because they express the PTH receptor and PTH 
administration expands their numbers 2-fold. 
Depletion of Nestin-expressing MSCs in vivo leads 
to a loss of the most immature HSPCs, suggesting 
these cells are a critical niche component.  
Human MSCs that express Nestin have been recently 
identified in fetal marrow and reside in a population 
of marrow cells that are CD45−, CD235a−, CD31−, 
CD51+, and PDGFRα+. These cells are capable of 
forming mesenspheres in vitro, and support human 
hematopoiesis ex vivo. Mesenspheres support 
hematopoiesis through expression of various 
cytokines such as stem cell factor. Cells capable of 
mesensphere formation and HSPC support have also 
been isolated from human cord blood. These cells 
from cord blood are defined as CD45−, CD31−, 
CD71−, CD146+, CD105+, and nestin+ 
Adipocytes 
Although many cell types have been identified as 
positive regulators of HSPCs in the marrow, 
adipocytes have been recognized as an inhibitory 
component. This was demonstrated using the A-ZIP 
strain, which has virtually no adipose tissue, by 
forced expression of a dominant-negative CCAAT-
Enhancer-Binding Protein (C/EBPα). The A-ZIP 
strain has hematopoiesis in marrow cavities that are 
normally filled with adipose tissue. This strain is also 
able to reconstitute their marrow faster than WT 
littermates after myeloablative injury.  
Moreover, inhibiting adipogenesis through 
peroxisome proliferator-activated receptor-γ 
antagonism leads to faster recovery of peripheral 
white blood cells after myeloablative injury and 
marrow transplant. Marrow cavities with higher 
adipose content contain fewer HSPCs compared with 
cavities without adipose, reinforcing the concept that 
adipocytes are an inhibitory component of the niche. 
However, the adipose-initiated signals resulting in 
HSPC inhibition remain unexplored. There is still a 
lot to learn about this cell type, although studies have 
suggested they have a transcriptome distinct from 
white adipose tissue. More recent insights on bone 
marrow fat are reviewed elsewhere.  
Critical Regulatory Signals in the HSC Niche 
This study was the first to show the importance of 
CXCL12 for haematopoiesis in the marrow. CXCL12 
acts through its receptor C-X-C chemokine receptor 
type 4, which has also been shown to be required for 
haematopoiesis in the marrow and engraftment of 
transplanted HSCs. The HSPC-mobilizing agent 
granulocyte colony-stimulating factor (GCSF) acts 
through this signalling axis by decreasing marrow 
CXCL12 while simultaneously up regulating 
CXCR4.  
HSPC egress from the marrow could be blunted by 
blocking CXCR4 or by preventing CXCL12 
degradation by neutrophil-derived elastase. Other 
groups have reported that in response to GCSF, 
CXCR4 is cleaved on HSPCs, which prevents them 
from responding to marrow CXCL12, facilitating 
mobilization from the marrow. The role of CXCR4 in 
HSPC homing has also been demonstrated by 
inhibiting Gαi with pertussis toxin (PTX). PTX 
diminishes the ability of HSPCs to respond to 
CXCL12, reducing the engraftment potential of these 
cells. Many cells in the marrow express CXCL12, but 
the highest expression of CXCL12 is observed in a 
subset of mesenchymal cells called CXCL12-
abundant reticular (CAR) cells. CAR cells reside in 
the bone marrow at both vascular and endosteal sites 
associated with HSPC residence. 
Circadian rhythms 
The action of circadian rhythms on the HSC niche 
highlights the fundamental role of CXCL12 in the 
regulation of HSCs and also aligns the marrow 
microenvironment with multiple hormonal systems. 
HSPCs are regulated in 3 dimensions not only by 
their niche but also through oscillation of circadian 
rhythms. This was first shown as circadian rhythms 
alter colony-forming potential in peripheral blood 
over the course of the day. Circadian rhythms also 
modulate catecholamine levels, which have been 
previously shown to influence HSPC self-renewal 
and exit from the marrow. 
 
Sympathetic nervous system signals 
Signals from the sympathetic nervous system (SNS) 
have been recently identified as an unexpected 
component in the regulation of HSPCs in the marrow. 
It has been previously demonstrated that the SNS can 
regulate bone formation through β2-adrenergic 
signals that stimulate expression of Receptor 
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activator of nuclear factor kappa-B ligand in 
osteoblasts. Genetic inhibition of myelination, 
resulting in decreased nerve conductance, prevents 
HSPC egress from the marrow. Egress of HSPCs can 
also be blocked by depleting catecholamine stores 
with 6-hydroxydopamine, suggesting that 
sympathetic signals are regulating this process.  
Human HSPCs express both dopamine and 
adrenergic receptors, suggesting they are able to 
respond to SNS-mediated signals. Treatment of 
HSPCs with dopamine agonists enhanced colony 
formation in vitro, but only in the presence of 
myeloid cytokine GCSF, or granulocyte-macrophage 
colony-stimulating factor. Pretreatment of human 
HSPCs with dopamine agonists enhanced their ability 
to engraft immunocompromised. This effect is 
dopamine-dependent because treatment of HSPCs 
with dopamine antagonists decreases their ability to 
engraft. NE treatment of HSPCs promotes migration 
through expression of Matrix Metalloproteinase-2 but 
also enhances engraftment capabilities in vivo and 
colony formation in vitro. 
Signaling through GαS 
The heterotrimeric GαS subunit is an integration 
point for many prohematopoietic signals that require 
activation of protein kinase A, and osteoblasts 
express many of these GαS-coupled receptors 
(PTH1R, PTGER2, PTGER4, and ADRB2). 
Interestingly, many of the critical signals highlighted 
in this review signal through GαS (PTH, 
prostaglandin, and β-adrenergic signals,).  
Conditional deletion of GαS using the inducible Mx-
1-Cre bypasses the lethality of a GαS global 
knockout. HSPCs have impaired homing capacity 
and do not respond to mobilizing agents such as 
GCSF. Constitutive activation of GαS in WT HSPCs 
by cholera treatment before transplant increased their 
engraftment potential 2-fold. Genetic ablation of GαS 
specifically in osteoprogenitors using Osx-Cre leads 
to a decrease in trabecular bone and B-lymphocyte 
precursors.  
Mechanistically, a loss of GαS leads to decreased IL-
7 expression in osteoblasts, which is required for 
their ability to support normal B and T cell 
development. This suggests that GαS is required in 
osteoblasts to support normal lymphopoiesis in the 
marrow. Removing GαS from the terminally 
differentiated osteocyte using Dentin Matrix Acidic 
Phosphoprotein (Dmp1)-Cre leads to depletion of 
trabecular bone. Loss of GαS in osteocytes is 
required for this phenotype.  
Transplantation of WT marrow into osteocyte 
GαS−/− leads to myeloproliferation, whereas this 
process is attenuated when osteocyte GαS−/− marrow 
is transplanted into WT recipients. Gain of function 
for GαS in osteoblasts was demonstrated by 
expressing a constitutively active engineered 5-
Hydroxytryptamine receptor 4 receptor. Dramatic 
bone remodeling with expansion of stromal 
populations (osteoblasts, MSCs, and endothelial 
cells) and fibrosis in the marrow. Even though these 
HSPC-supportive populations are expanded in the 
setting of constitutive GαS signaling in osteoblasts, 
they suppress expression of genes required for HSPC 
maintenance.  
These studies provide evidence that GαS signaling 
has pleomorphic effects that are required both 
intrinsically and extrinsically in the marrow to 
support normal hematopoiesis and marrow structure. 
In addition to GαS signals, a role of orphan G 
protein-coupled receptors (GPRs) in the niche is 
beginning to emerge. Orphan receptor GPR56 has 
been characterized by Saito et al as a component of 
both benign and malignant hematopoiesis. 
Expression of GPR56 by HSPCs facilitates matrix 
adhesion into the niche, which is transduced into the 
cell by activation of RhoA signaling. In leukemic 
cells, signals downstream of GPR56 mediate both 
chemotherapy resistance and cell survival.  
This study provides evidence that orphan GPCR 
signals are a component of the HSC niche and can be 
co-opted during malignant transformation. 
CONCLUSION: 
Various components in the marrow tightly regulate 
HSPC function to maintain the stem cell pool while 
allowing normal hematopoiesis to occur. Osteoblasts, 
their mesenchymal precursors, and SNS neurons have 
been shown to be important regulators of HSPCs not 
only through direct contact but also through secreted 
signals. The heterogeneity of these signals is a 
therapeutic advantage because it provides multiple 
targets in the investigation for new agents for 
hematopoietic recovery and to increase stem cell 
yields for transplantation. Furthermore, niche 
stimulation may also restore normal hematopoiesis as 
a possible adjuvant treatment for malignancies.  
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